Zura Bio announced that the Phase 2 TibuSHIELD study of tibulizumab failed to meet its key efficacy targets in hidradenitis suppurativa, leading the company to discontinue development of the drug in that indication. Concurrently, programs for systemic sclerosis and polymyalgia rheumatica will proceed as planned.